GlassScriptPhysician profile
Shafia Bhutto
NPI 1982807335
$2,765.52
in general payments reported to CMS, 2019-2025
31 companies · $581 in 2025
The $581 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $105 · 2021: $169 · 2022: $667 · 2023: $352 · 2024: $576 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.46 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $252.27 | 2023-2025 | Veozah |
| Aspira Women'S Health INC | $238.24 | 2021-2022 | |
| Organon LLC | $230.54 | 2023-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $205.61 | 2021-2025 | |
| Hologic Sales and Service, LLC | $200.80 | 2020-2025 | Third Wave, Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $163.59 | 2019-2024 | |
| Coopersurgical, INC. | $151.91 | 2021-2023 | Wallach Cryosurgical Equipment, Paragard T 380a |
| Exeltis, USA INC. | $121.24 | 2019-2025 | Slynd |
| Amgen INC. | $113.28 | 2019-2025 | Evenity, Prolia |
| Myovant Sciences INC. | $111.74 | 2021-2022 | |
| Sage Therapeutics, LLC | $101.45 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $97.94 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $73.62 | 2020-2025 | |
| Therapeuticsmd, INC. | $60.28 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $39.90 | 2022 | |
| Meditrina | $36.33 | 2021-2023 | |
| Amag Pharmaceuticals, INC. | $34.36 | 2019 | |
| Duchesnay USA Incorporated | $29.39 | 2019 | |
| Merck Sharp & Dohme LLC | $26.75 | 2019 | |
| Mylan Pharmaceuticals INC. | $25.50 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.78 | 2025 | Qelbree |
| Lupin INC. | $22.89 | 2019 | |
| Radius Health, INC. | $20.57 | 2019 | |
| Smith+Nephew, INC. | $18.70 | 2019 | |
| Shield Therapeutics INC | $18.63 | 2022 | |
| Avion Pharmaceuticals | $16.62 | 2023 | Balcoltra |
| Aesculap, INC. | $14.92 | 2019 | |
| Evofem Biosciences, INC. | $14.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.61 | 2019 | |
| Agile Therapeutics, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shafia Bhutto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.